{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:53:35Z","timestamp":1790952815364,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["FP7-HEALTH-2011.1.4-4-280873"],"award-info":[{"award-number":["FP7-HEALTH-2011.1.4-4-280873"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Innovation Fund Denmark"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The clinical development of an effective Chlamydia vaccine requires in-depth understanding of how well protective pre-clinical immune signatures translate to humans. Here, we report a comparative immunological characterization of CTH522\/CAF\u00ae01 in female mice and humans. We find a range of immune signatures that translate from mouse to human, including a Th1\/Th17 cytokine profile and antibody functionality. We identify vaccine-induced T cell epitopes, conserved among Chlamydia serovars, and previously found in infected individuals. Using the mouse model, we show that the common immune signature protected against ascending infection in mice, and vaccine induced antibodies could delay bacterial ascension to the oviduct, as well as development of pathology, in a T cell depleted mouse model. Finally, we demonstrate long-lasting immunity and protection of mice one year after vaccination. Based on the results obtained in the present study, we propose to further investigate CTH522\/CAF\u00ae01 in a phase IIb study.<\/jats:p>","DOI":"10.1038\/s41467-024-45526-2","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T07:02:57Z","timestamp":1708671777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Immune signature of Chlamydia vaccine CTH522\/CAF\u00ae01 translates from mouse-to-human and induces durable protection in mice"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5640-3496","authenticated-orcid":false,"given":"Anja W.","family":"Olsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0085-7883","authenticated-orcid":false,"given":"Ida","family":"Rosenkrands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0502-2976","authenticated-orcid":false,"given":"Christina S.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9044-1341","authenticated-orcid":false,"given":"Hannah M.","family":"Cheeseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1361-3634","authenticated-orcid":false,"given":"Max P.","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8536-0141","authenticated-orcid":false,"given":"Jes","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4936-1718","authenticated-orcid":false,"given":"Robin J.","family":"Shattock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8373-7774","authenticated-orcid":false,"given":"Frank","family":"Follmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"45526_CR1","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran, B., S Arunachalam, P. & O'Hagan, D. T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454\u2013475 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"45526_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1473-3099(19)30279-8","volume":"19","author":"S Abraham","year":"2019","unstructured":"Abraham, S. et al. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect. Dis. 19, 1091\u20131100 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"45526_CR3","doi-asserted-by":"publisher","first-page":"e0143304","DOI":"10.1371\/journal.pone.0143304","volume":"10","author":"L Newman","year":"2015","unstructured":"Newman, L. et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One 10, e0143304 (2015).","journal-title":"PLoS One"},{"key":"45526_CR4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S0091-7435(02)00058-0","volume":"36","author":"TA Farley","year":"2003","unstructured":"Farley, T. A., Cohen, D. A. & Elkins, W. Asymptomatic sexually transmitted diseases: the case for screening. Prev. Med. 36, 502\u2013509 (2003).","journal-title":"Prev. Med."},{"key":"45526_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/00007435-199207000-00001","volume":"19","author":"L Westrom","year":"1992","unstructured":"Westrom, L., Joesoef, R., Reynolds, G., Hagdu, A. & Thompson, S. E. Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm. Dis. 19, 185\u2013192 (1992).","journal-title":"Sex Transm. Dis."},{"key":"45526_CR6","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.4049\/jimmunol.158.7.3344","volume":"158","author":"LL Perry","year":"1997","unstructured":"Perry, L. L., Feilzer, K. & Caldwell, H. D. Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-gamma-dependent and -independent pathways. J. Immunol. 158, 3344\u20133352 (1997).","journal-title":"J. Immunol."},{"key":"45526_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1128\/iai.57.1.299-301.1989","volume":"57","author":"RG Rank","year":"1989","unstructured":"Rank, R. G. & Batteiger, B. E. Protective role of serum antibody in immunity to chlamydial genital infection. Infect. Immun. 57, 299\u2013301 (1989).","journal-title":"Infect. Immun."},{"key":"45526_CR8","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1128\/iai.63.12.4704-4714.1995","volume":"63","author":"TW Cotter","year":"1995","unstructured":"Cotter, T. W. et al. Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection. Infect. Immun. 63, 4704\u20134714 (1995).","journal-title":"Infect. Immun."},{"key":"45526_CR9","doi-asserted-by":"publisher","first-page":"8063","DOI":"10.4049\/jimmunol.0804375","volume":"182","author":"L Kari","year":"2009","unstructured":"Kari, L. et al. Chlamydia trachomatis native major outer membrane protein induces partial protection in nonhuman primates: implication for a trachoma transmission-blocking vaccine. J. Immunol. 182, 8063\u20138070 (2009).","journal-title":"J. Immunol."},{"key":"45526_CR10","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/infdis\/jiv137","volume":"212","author":"AW Olsen","year":"2015","unstructured":"Olsen, A. W., Follmann, F., Erneholm, K., Rosenkrands, I. & Andersen, P. Protection against Chlamydia trachomatis infection and upper genital tract pathological changes by vaccine-promoted neutralizing antibodies directed to the VD4 of the major outer membrane protein. J. Infect. Dis. 212, 978\u2013989 (2015).","journal-title":"J. Infect. Dis."},{"key":"45526_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1046\/j.0019-2805.2001.01354.x","volume":"105","author":"T Moore","year":"2002","unstructured":"Moore, T. et al. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology 105, 213\u2013221 (2002).","journal-title":"Immunology"},{"key":"45526_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1086\/432070","volume":"192","author":"CR Cohen","year":"2005","unstructured":"Cohen, C. R. et al. Immunoepidemiologic profile of Chlamydia trachomatis infection: importance of heat-shock protein 60 and interferon- gamma. J. Infect. Dis. 192, 591\u2013599 (2005).","journal-title":"J. Infect. Dis."},{"key":"45526_CR13","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1093\/infdis\/jiw485","volume":"214","author":"AN Russell","year":"2016","unstructured":"Russell, A. N. et al. Identification of Chlamydia trachomatis antigens recognized by T cells from highly exposed women who limit or resist genital tract infection. J. Infect. Dis. 214, 1884\u20131892 (2016).","journal-title":"J. Infect. Dis."},{"key":"45526_CR14","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.3389\/fimmu.2018.01981","volume":"9","author":"RK Bakshi","year":"2018","unstructured":"Bakshi, R. K. et al. An adaptive Chlamydia trachomatis-specific IFN-gamma-producing CD4(+) T cell response is associated with protection against chlamydia reinfection in women. Front Immunol. 9, 1981 (2018).","journal-title":"Front Immunol."},{"key":"45526_CR15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/infdis\/jiz087","volume":"220","author":"TB Poston","year":"2019","unstructured":"Poston, T. B. et al. Cervical cytokines associated with Chlamydia trachomatis susceptibility and protection. J. Infect. Dis. 220, 330\u2013339 (2019).","journal-title":"J. Infect. Dis."},{"key":"45526_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/infdis\/jiv438","volume":"213","author":"AN Russell","year":"2016","unstructured":"Russell, A. N. et al. Analysis of factors driving incident and ascending infection and the role of serum antibody in Chlamydia trachomatis genital tract infection. J. Infect. Dis. 213, 523\u2013531 (2016).","journal-title":"J. Infect. Dis."},{"key":"45526_CR17","doi-asserted-by":"publisher","first-page":"e13103","DOI":"10.1111\/aji.13103","volume":"81","author":"T Darville","year":"2019","unstructured":"Darville, T. et al. Anti-chlamydia IgG and IgA are insufficient to prevent endometrial chlamydia infection in women, and increased anti-chlamydia IgG is associated with enhanced risk for incident infection. Am. J. Reprod. Immunol. 81, e13103 (2019).","journal-title":"Am. J. Reprod. Immunol."},{"key":"45526_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/OLQ.0b013e3181557c25","volume":"35","author":"RB Ness","year":"2008","unstructured":"Ness, R. B. et al. Chlamydia antibodies, chlamydia heat shock protein, and adverse sequelae after pelvic inflammatory disease: the PID Evaluation and Clinical Health (PEACH) Study. Sex Transm. Dis. 35, 129\u2013135 (2008).","journal-title":"Sex Transm. Dis."},{"key":"45526_CR19","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1128\/iai.39.3.1491-1494.1983","volume":"39","author":"RC Brunham","year":"1983","unstructured":"Brunham, R. C., Kuo, C. C., Cles, L. & Holmes, K. K. Correlation of host immune response with quantitative recovery of Chlamydia trachomatis from the human endocervix. Infect. Immun. 39, 1491\u20131494 (1983).","journal-title":"Infect. Immun."},{"key":"45526_CR20","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1086\/528378","volume":"197","author":"F Follmann","year":"2008","unstructured":"Follmann, F. et al. Antigenic profiling of a Chlamydia trachomatis gene-expression library. J. Infect. Dis. 197, 897\u2013905 (2008).","journal-title":"J. Infect. Dis."},{"key":"45526_CR21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1086\/590670","volume":"198","author":"J Hansen","year":"2008","unstructured":"Hansen, J. et al. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. J. Infect. Dis. 198, 758\u2013767 (2008).","journal-title":"J. Infect. Dis."},{"key":"45526_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/imm.12520","volume":"146","author":"S Pal","year":"2015","unstructured":"Pal, S., Tatarenkova, O. V. & de la Maza, L. M. A vaccine formulated with the major outer membrane protein can protect C3H\/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge. Immunology 146, 432\u2013443 (2015).","journal-title":"Immunology"},{"key":"45526_CR23","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.vaccine.2017.02.020","volume":"35","author":"S Pal","year":"2017","unstructured":"Pal, S., Tifrea, D. F., Follmann, F., Andersen, P. & de la Maza, L. M. The cationic liposomal adjuvants CAF01 and CAF09 formulated with the major outer membrane protein elicit robust protection in mice against a Chlamydia muridarum respiratory challenge. Vaccine 35, 1705\u20131711 (2017).","journal-title":"Vaccine"},{"key":"45526_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/infdis\/jiz438","volume":"221","author":"DF Tifrea","year":"2020","unstructured":"Tifrea, D. F., Pal, S. & de la Maza, L. M. A recombinant Chlamydia trachomatis MOMP vaccine elicits cross-serogroup protection in mice against vaginal shedding and infertility. J. Infect. Dis. 221, 191\u2013200 (2020).","journal-title":"J. Infect. Dis."},{"key":"45526_CR25","doi-asserted-by":"publisher","first-page":"e13171","DOI":"10.1371\/journal.pone.0013171","volume":"5","author":"A Nunes","year":"2010","unstructured":"Nunes, A., Nogueira, P. J., Borrego, M. J. & Gomes, J. P. Adaptive evolution of the Chlamydia trachomatis dominant antigen reveals distinct evolutionary scenarios for B- and T-cell epitopes: worldwide survey. PLoS One 5, e13171 (2010).","journal-title":"PLoS One"},{"key":"45526_CR26","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.3389\/fimmu.2017.01652","volume":"8","author":"AW Olsen","year":"2017","unstructured":"Olsen, A. W., Lorenzen, E. K., Rosenkrands, I., Follmann, F. & Andersen, P. Protective effect of vaccine promoted neutralizing antibodies against the intracellular pathogen Chlamydia trachomatis. Front. Immunol. 8, 1652 (2017).","journal-title":"Front. Immunol."},{"key":"45526_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1078\/1438-4221-00238","volume":"293","author":"A Oehme","year":"2003","unstructured":"Oehme, A., Gaschler, G. & Straube, E. Genotyping of Chlamydia trachomatis strains from cultured isolates and nucleic acid amplification test-positive specimens. Int. J. Med. Microbiol. 293, 225\u2013228 (2003).","journal-title":"Int. J. Med. Microbiol."},{"key":"45526_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0157-x","volume":"5","author":"N Nguyen","year":"2020","unstructured":"Nguyen, N. et al. Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge. NPJ Vaccines 5, 7 (2020).","journal-title":"NPJ Vaccines"},{"key":"45526_CR29","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.xphs.2018.02.005","volume":"107","author":"F Rose","year":"2018","unstructured":"Rose, F. et al. Unusual self-assembly of the recombinant Chlamydia trachomatis major outer membrane protein-based fusion antigen CTH522 into protein nanoparticles. J. Pharm. Sci. 107, 1690\u20131700 (2018).","journal-title":"J. Pharm. Sci."},{"key":"45526_CR30","doi-asserted-by":"publisher","first-page":"e68934","DOI":"10.1371\/journal.pone.0068934","volume":"8","author":"VA Feher","year":"2013","unstructured":"Feher, V. A. et al. A 3-dimensional trimeric beta-barrel model for Chlamydia MOMP contains conserved and novel elements of Gram-negative bacterial porins. PLoS One 8, e68934 (2013).","journal-title":"PLoS One"},{"key":"45526_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/srep19570","volume":"6","author":"NP Knudsen","year":"2016","unstructured":"Knudsen, N. P. et al. Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. Sci. Rep. 6, 19570 (2016).","journal-title":"Sci. Rep."},{"key":"45526_CR32","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1128\/IAI.68.3.1719-1723.2000","volume":"68","author":"L Ortiz","year":"2000","unstructured":"Ortiz, L., Angevine, M., Kim, S. K., Watkins, D. & DeMars, R. T-cell epitopes in variable segments of Chlamydia trachomatis major outer membrane protein elicit serovar-specific immune responses in infected humans. Infect. Immun. 68, 1719\u20131723 (2000).","journal-title":"Infect. Immun."},{"key":"45526_CR33","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.4049\/jimmunol.157.10.4554","volume":"157","author":"L Ortiz","year":"1996","unstructured":"Ortiz, L. et al. Chlamydia trachomatis major outer membrane protein (MOMP) epitopes that activate HLA class II-restricted T cells from infected humans. J. Immunol. 157, 4554\u20134567 (1996).","journal-title":"J. Immunol."},{"key":"45526_CR34","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1128\/iai.58.5.1450-1455.1990","volume":"58","author":"GM Zhong","year":"1990","unstructured":"Zhong, G. M., Reid, R. E. & Brunham, R. C. Mapping antigenic sites on the major outer membrane protein of Chlamydia trachomatis with synthetic peptides. Infect. Immun. 58, 1450\u20131455 (1990).","journal-title":"Infect. Immun."},{"key":"45526_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00312-9","volume":"6","author":"AW Olsen","year":"2021","unstructured":"Olsen, A. W., Rosenkrands, I., Holland, M. J., Andersen, P. & Follmann, F. A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C\/C-related complex serovars. NPJ Vaccines 6, 58 (2021).","journal-title":"NPJ Vaccines"},{"key":"45526_CR36","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1095\/biolreprod57.4.847","volume":"57","author":"RN Fichorova","year":"1997","unstructured":"Fichorova, R. N., Rheinwald, J. G. & Anderson, D. J. Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. Biol. Reprod. 57, 847\u2013855 (1997).","journal-title":"Biol. Reprod."},{"key":"45526_CR37","doi-asserted-by":"publisher","first-page":"8047","DOI":"10.4049\/jimmunol.0801592","volume":"182","author":"T Lindenstrom","year":"2009","unstructured":"Lindenstrom, T. et al. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol. 182, 8047\u20138055 (2009).","journal-title":"J. Immunol."},{"key":"45526_CR38","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1128\/IAI.00550-12","volume":"80","author":"T Lindenstrom","year":"2012","unstructured":"Lindenstrom, T. et al. Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset. Infect. Immun. 80, 3533\u20133544 (2012).","journal-title":"Infect. Immun."},{"key":"45526_CR39","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1016\/j.vaccine.2014.10.036","volume":"32","author":"JT van Dissel","year":"2014","unstructured":"van Dissel, J. T. et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine 32, 7098\u20137107 (2014).","journal-title":"Vaccine"},{"key":"45526_CR40","doi-asserted-by":"publisher","first-page":"e76664","DOI":"10.1371\/journal.pone.0076664","volume":"8","author":"DW Andrew","year":"2013","unstructured":"Andrew, D. W. et al. The duration of Chlamydia muridarum genital tract infection and associated chronic pathological changes are reduced in IL-17 knockout mice but protection is not increased further by immunization. PLoS One 8, e76664 (2013).","journal-title":"PLoS One"},{"key":"45526_CR41","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/mi.2009.100","volume":"2","author":"SA Khader","year":"2009","unstructured":"Khader, S. A., Gaffen, S. L. & Kolls, J. K. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol. 2, 403\u2013411 (2009).","journal-title":"Mucosal Immunol."},{"key":"45526_CR42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.coi.2015.03.007","volume":"34","author":"N Schmitt","year":"2015","unstructured":"Schmitt, N. & Ueno, H. Regulation of human helper T cell subset differentiation by cytokines. Curr. Opin. Immunol. 34, 130\u2013136 (2015).","journal-title":"Curr. Opin. Immunol."},{"key":"45526_CR43","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/ni.2552","volume":"14","author":"K Hirota","year":"2013","unstructured":"Hirota, K. et al. Plasticity of Th17 cells in Peyer\u2019s patches is responsible for the induction of T cell-dependent IgA responses. Nat. Immunol. 14, 372\u2013379 (2013).","journal-title":"Nat. Immunol."},{"key":"45526_CR44","doi-asserted-by":"publisher","unstructured":"Yount, K. S. et al. Unique T cell signatures are associated with reduced Chlamydia trachomatis reinfection in a highly exposed cohort. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.08.02.551709 (2023).","DOI":"10.1101\/2023.08.02.551709"},{"key":"45526_CR45","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/2049-632X.12034","volume":"67","author":"A Hjelholt","year":"2013","unstructured":"Hjelholt, A., Christiansen, G., Sorensen, U. S. & Birkelund, S. IgG subclass profiles in normal human sera of antibodies specific to five kinds of microbial antigens. Pathog. Dis. 67, 206\u2013213 (2013).","journal-title":"Pathog. Dis."},{"key":"45526_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/infdis\/168.2.415","volume":"168","author":"GI Byrne","year":"1993","unstructured":"Byrne, G. I. et al. Workshop on in vitro neutralization of Chlamydia trachomatis: summary of proceedings. J. Infect. Dis. 168, 415\u2013420 (1993).","journal-title":"J. Infect. Dis."},{"key":"45526_CR47","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1128\/iai.59.10.3811-3814.1991","volume":"59","author":"H Su","year":"1991","unstructured":"Su, H., Spangrude, G. J. & Caldwell, H. D. Expression of Fc gamma RIII on HeLa 229 cells: possible effect on in vitro neutralization of Chlamydia trachomatis. Infect. Immun. 59, 3811\u20133814 (1991).","journal-title":"Infect. Immun."},{"key":"45526_CR48","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/icb.2013.110","volume":"92","author":"CW Armitage","year":"2014","unstructured":"Armitage, C. W. et al. Divergent outcomes following transcytosis of IgG targeting intracellular and extracellular chlamydial antigens. Immunol. Cell Biol. 92, 417\u2013426 (2014).","journal-title":"Immunol. Cell Biol."},{"key":"45526_CR49","doi-asserted-by":"publisher","first-page":"1057375","DOI":"10.3389\/fimmu.2022.1057375","volume":"13","author":"E Lorenzen","year":"2022","unstructured":"Lorenzen, E. et al. Multi-component prime-boost Chlamydia trachomatis vaccination regimes induce antibody and T cell responses and accelerate clearance of infection in a non-human primate model. Front. Immunol. 13, 1057375 (2022).","journal-title":"Front. Immunol."},{"key":"45526_CR50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/icb.2015.79","volume":"94","author":"S Boje","year":"2016","unstructured":"Boje, S. et al. A multi-subunit Chlamydia vaccine inducing neutralizing antibodies and strong IFN-gamma(+) CMI responses protects against a genital infection in minipigs. Immunol. Cell Biol. 94, 185\u2013195 (2016).","journal-title":"Immunol. Cell Biol."},{"key":"45526_CR51","doi-asserted-by":"publisher","first-page":"575","DOI":"10.4049\/jimmunol.138.2.575","volume":"138","author":"YX Zhang","year":"1987","unstructured":"Zhang, Y. X., Stewart, S., Joseph, T., Taylor, H. R. & Caldwell, H. D. Protective monoclonal antibodies recognize epitopes located on the major outer membrane protein of Chlamydia trachomatis. J. Immunol. 138, 575\u2013581 (1987).","journal-title":"J. Immunol."},{"key":"45526_CR52","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1128\/iai.61.4.1365-1370.1993","volume":"61","author":"Z Qu","year":"1993","unstructured":"Qu, Z., Cheng, X., de la Maza, L. M. & Peterson, E. M. Characterization of a neutralizing monoclonal antibody directed at variable domain I of the major outer membrane protein of Chlamydia trachomatis C-complex serovars. Infect. Immun. 61, 1365\u20131370 (1993).","journal-title":"Infect. Immun."},{"key":"45526_CR53","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1128\/iai.62.5.1576-1583.1994","volume":"62","author":"G Zhong","year":"1994","unstructured":"Zhong, G., Berry, J. & Brunham, R. C. Antibody recognition of a neutralization epitope on the major outer membrane protein of Chlamydia trachomatis. Infect. Immun. 62, 1576\u20131583 (1994).","journal-title":"Infect. Immun."},{"key":"45526_CR54","unstructured":"Morrison, R. P., Manning, D. S. & Caldwell, H. D. Immunology of Chlamydia trachomatis infections: immunoprotective and immunopathogenetic responses. In: Sexually Transmitted Diseases (ed Quinn, T. C.) 57\u201384 (Raven Press, 1992)."},{"key":"45526_CR55","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","volume":"9","author":"G Dekkers","year":"2017","unstructured":"Dekkers, G. et al. Affinity of human IgG subclasses to mouse Fc gamma receptors. MAbs 9, 767\u2013773 (2017).","journal-title":"MAbs"},{"key":"45526_CR56","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1128\/iai.65.8.3065-3073.1997","volume":"65","author":"T Darville","year":"1997","unstructured":"Darville, T. et al. Mouse strain-dependent variation in the course and outcome of chlamydial genital tract infection is associated with differences in host response. Infect. Immun. 65, 3065\u20133073 (1997).","journal-title":"Infect. Immun."},{"key":"45526_CR57","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/2049-632X.12164","volume":"72","author":"GL Sturdevant","year":"2014","unstructured":"Sturdevant, G. L. & Caldwell, H. D. Innate immunity is sufficient for the clearance of Chlamydia trachomatis from the female mouse genital tract. Pathog. Dis. 72, 70\u201373 (2014).","journal-title":"Pathog. Dis."},{"key":"45526_CR58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0165-0378(97)00061-2","volume":"36","author":"P Brandtzaeg","year":"1997","unstructured":"Brandtzaeg, P. Mucosal immunity in the female genital tract. J. Reprod. Immunol. 36, 23\u201350 (1997).","journal-title":"J. Reprod. Immunol."},{"key":"45526_CR59","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.immuni.2004.05.007","volume":"20","author":"M Yoshida","year":"2004","unstructured":"Yoshida, M. et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 20, 769\u2013783 (2004).","journal-title":"Immunity"},{"key":"45526_CR60","doi-asserted-by":"publisher","first-page":"4388","DOI":"10.1073\/pnas.1012861108","volume":"108","author":"Z Li","year":"2011","unstructured":"Li, Z. et al. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc. Natl Acad. Sci. USA 108, 4388\u20134393 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"45526_CR61","doi-asserted-by":"publisher","first-page":"10542","DOI":"10.1128\/JVI.05441-11","volume":"85","author":"L Lu","year":"2011","unstructured":"Lu, L. et al. A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J. Virol. 85, 10542\u201310553 (2011).","journal-title":"J. Virol."},{"key":"45526_CR62","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.fertnstert.2008.08.128","volume":"92","author":"N Al-Mously","year":"2009","unstructured":"Al-Mously, N., Cross, N. A., Eley, A. & Pacey, A. A. Real-time polymerase chain reaction shows that density centrifugation does not always remove Chlamydia trachomatis from human semen. Fertil Steril 92, 1606\u20131615 (2009).","journal-title":"Fertil Steril"},{"key":"45526_CR63","unstructured":"Flurkey, K., Currer, J. M. & Harrison, D. E. Mouse models in aging research. In: The Mouse in Biomedical Research, 2nd edn, Vol. 3 (eds Fox, J. G., Barthold, S. W., Davisson, M. T., Newcomer, C. E. Quimby, F. W., Smith, A. L.) 637\u2013672 (Elsevier, 2007)."},{"key":"45526_CR64","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nri2274","volume":"8","author":"RA Seder","year":"2008","unstructured":"Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8, 247\u2013258 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"45526_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6377","volume":"5","author":"KK McKinstry","year":"2014","unstructured":"McKinstry, K. K. et al. Effector CD4 T-cell transition to memory requires late cognate interactions that induce autocrine IL-2. Nat. Commun. 5, 5377 (2014).","journal-title":"Nat. Commun."},{"key":"45526_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00239-7","volume":"5","author":"S Pal","year":"2020","unstructured":"Pal, S. et al. Vaccination with the recombinant major outer membrane protein elicits long-term protection in mice against vaginal shedding and infertility following a Chlamydia muridarum genital challenge. NPJ Vaccines 5, 90 (2020).","journal-title":"NPJ Vaccines"},{"key":"45526_CR67","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.4049\/jimmunol.162.6.3541","volume":"162","author":"LL Perry","year":"1999","unstructured":"Perry, L. L. et al. Differential sensitivity of distinct Chlamydia trachomatis isolates to IFN-gamma-mediated inhibition. J. Immunol. 162, 3541\u20133548 (1999).","journal-title":"J. Immunol."},{"key":"45526_CR68","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/0264-410X(95)00017-U","volume":"13","author":"H Su","year":"1995","unstructured":"Su, H., Parnell, M. & Caldwell, H. D. Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection. Vaccine 13, 1023\u20131032 (1995).","journal-title":"Vaccine"},{"key":"45526_CR69","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/mi.2013.120","volume":"7","author":"YY Wang","year":"2014","unstructured":"Wang, Y. Y. et al. IgG in cervicovaginal mucus traps HSV and prevents vaginal herpes infections. Mucosal Immunol. 7, 1036\u20131044 (2014).","journal-title":"Mucosal Immunol."},{"key":"45526_CR70","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1080\/14760584.2022.2117694","volume":"21","author":"AH Borges","year":"2022","unstructured":"Borges, A. H., Follmann, F. & Dietrich, J. Chlamydia trachomatis vaccine development\u2014a view on the current challenges and how to move forward. Expert Rev. Vaccines 21, 1555\u20131567 (2022).","journal-title":"Expert Rev. Vaccines"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45526-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45526-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45526-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T10:06:25Z","timestamp":1708682785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45526-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["45526"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-45526-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3095572\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"22 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.W.O., I.R. and F.F. are co-inventors of a patent (WO2014146663A1) relating to <i>C.t<\/i>. vaccines. All rights have been assigned to Statens Serum Institut, a Danish not-for-profit governmental institute. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1665"}}